Brief: Alterity's ATH434 Prevents Loss Of Brain Cells In Parkinson's Disease Animal Model
30/01/2023 11:28
Jan 30 (Reuters) - Alterity Therapeutics Ltd ATH.AX :
* ALTERITY’S ATH434 PREVENTS LOSS OF BRAIN CELLS IN
PARKINSON’S
DISEASE ANIMAL MODEL
Further company coverage: ATH.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital